Abstract
Aims
Vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, and higher levels of intraocular VEGF are observed in patients with active proliferative diabetic retinopathy. Meanwhile, whether serum VEGF level is associated with diabetic retinopathy (DR) or not is controversial.
Methods
To investigate the significance of serum VEGF levels in diabetic patients with DR, we measured serum VEGF levels in 138 type 2 diabetic patients hospitalized for treatment of a hyperglycemic state, all of whom were not complicated by VEGF-related diseases, such as malignancy, cardiovascular disease or infectious disease.
Results
Serum VEGF level was significantly increased in diabetic patients with DR as compared to those without DR. Moreover, multiple regression analysis and stepwise regression analysis revealed that body mass index and presence or absence of DR were associated with serum VEGF level; in particular, the presence of DR was strongly correlated with increased serum VEGF level.
Conclusions
Increased serum VEGF level may be closely associated with the presence of DR in type 2 diabetic patients. Whether this conclusion is true for general type 2 diabetic patients is a subject for future investigation because of several limitations of this study, including sample selection bias.
Similar content being viewed by others
References
Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol. 2004;14:123–30.
Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–5.
Caine GJ, Blann AD, Stonelake PS, et al. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest. 2003;33:883–90.
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.
Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol. 1998;82:561–8.
Burgos R, Simo R, Audi L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia. 1997;40:1107–9.
Tsai DC, Charng MJ, Lee FL, et al. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica. 2006;220:246–51.
Hernandez C, Lecube A, Segura RM, et al. Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2002;19:655–60.
Shinoda K, Ishida S, Kawashima S, et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol. 1999;83:834–7.
Lip PL, Chatterjee S, Caine GJ, et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol. 2004;88:1543–6.
Ozturk BT, Bozkurt B, Kerimoglu H, et al. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906–14.
Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483–8.
Japan Diabetes Society. Treatment guide for diabetes. Tokyo: Bunkodo Co., Ltd; 2007.
Davis MD. Vitreous contraction in proliferative diabetic retinopathy. Arch Ophthalmol. 1965;74:741–51.
The Committee on the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int. 2010;1:2–20.
Sharp PS, Al Mrayat M, Valabhji J, et al. Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologia. 1998;41:984–5.
Wasada T, Kawahara R, Katsumori K, et al. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism. 1998;47:27–30.
Kim NH, Kim KB, Kim DL, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med. 2004;21:545–51.
Karlsson S, Pettila V, Tenhunen J, et al. Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg. 2008;106:1820–6.
Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2006;7:253–9.
Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol. 2009;5:651–2.
Salven P, Manpaa H, Orpana A, et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997;3:647–51.
Liou JY, Shyu KG, Lu MJ, et al. Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. J Formos Med Assoc. 2006;105:377–83.
Panutsopulos D, Zafiropoulos A, Krambovitis E, et al. Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med. 2003;1:6.
Slevin M, Krupinski J, Slowik A, et al. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke. 2000;31:1863–70.
Liu H, Ren JG, Cooper WL, et al. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA. 2004;101:6605–10.
Ogata N, Matsuoka M, Matsuyama K, et al. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab. 2007;92:1176–9.
Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52:180–95.
Takahashi S, Nakamura Y, Nishijima T, et al. Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir Med. 2005;99:1125–31.
Nadar SK, Blann AD, Lip GY. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med. 2004;256:331–7.
Alber HF, Dulak J, Frick M, et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol. 2002;39:1951–5.
Emoto M, Fukuda N, Nakamori Y, et al. Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. Diabetologia. 2006;49:2217–8.
Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–23.
Manau D, Fabregues F, Penarrubia J, et al. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Hum Reprod. 2007;22:669–75.
Gadducci A, Tana R, Cosio S, et al. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008;66:10–20.
Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol. 2007;27:246–56.
Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–92.
Iwasaki T, Sano H. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels. Leuk Lymphoma. 2003;44:1275–9.
Acknowledgments
The authors declare that they have no conflict of interest. This work was not supported by any grant. We thank Tetsuro Takayama and Tatsuhiko Yagihashi for statistical advice.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takamiya, Y., Oikawa, Y., Hirose, H. et al. Higher level of serum vascular endothelial growth factor in type 2 diabetic patients with diabetic retinopathy hospitalized for hyperglycemic state. Diabetol Int 2, 19–25 (2011). https://doi.org/10.1007/s13340-011-0019-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-011-0019-x